Log in

NASDAQ:ALBOAlbireo Pharma News Headlines

$26.63
+0.86 (+3.34 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$25.90
Now: $26.63
$27.15
50-Day Range
$17.43
MA: $23.60
$27.43
52-Week Range
$11.26
Now: $26.63
$35.76
Volume138,482 shs
Average Volume69,652 shs
Market Capitalization$398.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92

Headlines

Albireo Pharma (NASDAQ ALBO) News Headlines

Source:
DateHeadline
Albireo Pharma Inc (NASDAQ:ALBO) Given Consensus Recommendation of "Buy" by BrokeragesAlbireo Pharma Inc (NASDAQ:ALBO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 6 at 2:52 AM
Albireo Pharma Inc (NASDAQ:ALBO) Expected to Post Quarterly Sales of $1.36 MillionAlbireo Pharma Inc (NASDAQ:ALBO) Expected to Post Quarterly Sales of $1.36 Million
www.americanbankingnews.com - May 30 at 3:18 AM
 Brokerages Expect Albireo Pharma Inc (NASDAQ:ALBO) to Announce -$1.66 Earnings Per Share Brokerages Expect Albireo Pharma Inc (NASDAQ:ALBO) to Announce -$1.66 Earnings Per Share
www.americanbankingnews.com - May 28 at 2:27 PM
BRIEF-Albireo Pharma Says May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $50 MillionBRIEF-Albireo Pharma Says May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $50 Million
www.reuters.com - May 27 at 11:07 PM
Albireo to Present at 2020 Jefferies Virtual Healthcare ConferenceAlbireo to Present at 2020 Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 26 at 9:34 AM
ALBO Albireo Pharma, Inc. Common StockALBO Albireo Pharma, Inc. Common Stock
www.nasdaq.com - May 21 at 11:49 PM
Albireo Pharma Inc to Post Q2 2020 Earnings of ($1.51) Per Share, Wedbush Forecasts (NASDAQ:ALBO)Albireo Pharma Inc to Post Q2 2020 Earnings of ($1.51) Per Share, Wedbush Forecasts (NASDAQ:ALBO)
www.americanbankingnews.com - May 14 at 1:55 PM
FY2023 Earnings Estimate for Albireo Pharma Inc (NASDAQ:ALBO) Issued By WedbushFY2023 Earnings Estimate for Albireo Pharma Inc (NASDAQ:ALBO) Issued By Wedbush
www.americanbankingnews.com - May 13 at 12:32 PM
The Consensus EPS Estimates For Albireo Pharma, Inc. (NASDAQ:ALBO) Just Fell DramaticallyThe Consensus EPS Estimates For Albireo Pharma, Inc. (NASDAQ:ALBO) Just Fell Dramatically
finance.yahoo.com - May 12 at 8:44 AM
Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported And Analysts Have Been Cutting Their EstimatesAlbireo Pharma, Inc. (NASDAQ:ALBO) Just Reported And Analysts Have Been Cutting Their Estimates
finance.yahoo.com - May 11 at 7:26 AM
Albireo Pharma, Inc.s (ALBO) CEO Ron Cooper on Q1 2020 Results - Earnings Call TranscriptAlbireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:43 AM
Albireo Pharma EPS misses by $0.87, beats on revenueAlbireo Pharma EPS misses by $0.87, beats on revenue
seekingalpha.com - May 7 at 12:15 PM
Albireo Reports Q1 2020 Financial Results and Provides Business UpdateAlbireo Reports Q1 2020 Financial Results and Provides Business Update
finance.yahoo.com - May 7 at 12:15 PM
Recap: Albireo Pharma Q1 EarningsRecap: Albireo Pharma Q1 Earnings
finance.yahoo.com - May 7 at 12:15 PM
How Does Albireo Pharma, Inc. (NASDAQ:ALBO) Affect Your Portfolio Volatility?How Does Albireo Pharma, Inc. (NASDAQ:ALBO) Affect Your Portfolio Volatility?
finance.yahoo.com - May 3 at 4:32 PM
Albireo to Report First Quarter 2020 Financial Results on May 7Albireo to Report First Quarter 2020 Financial Results on May 7
finance.yahoo.com - April 30 at 5:54 PM
Albireo Pharma Inc.Albireo Pharma Inc.
www.barrons.com - April 18 at 11:37 PM
Albireo to Present at 19th Annual Needham Healthcare ConferenceAlbireo to Present at 19th Annual Needham Healthcare Conference
finance.yahoo.com - April 7 at 3:46 PM
Albireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLDAlbireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLD
seekingalpha.com - March 10 at 1:00 PM
Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLDAlbireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
finance.yahoo.com - March 10 at 1:00 PM
Albireo Pharma, Inc. Just Reported And Analysts Have Been Cutting Their EstimatesAlbireo Pharma, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
finance.yahoo.com - March 4 at 12:33 PM
Albireo Pharma, Inc. (ALBO) Q4 2019 Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) Q4 2019 Earnings Call Transcript
www.nasdaq.com - March 2 at 7:31 PM
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2019 Results - Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2019 Results - Earnings Call Transcript
seekingalpha.com - March 2 at 7:31 PM
Albireo Pharma EPS beats by $1.02, beats on revenueAlbireo Pharma EPS beats by $1.02, beats on revenue
seekingalpha.com - March 2 at 9:31 AM
Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business UpdateAlbireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update
finance.yahoo.com - March 2 at 9:31 AM
Albireo Recognizes Rare Disease Day and Supports Global Effort to “Reframe Rare” By Highlighting the Challenges of Cholestatic Liver DisordersAlbireo Recognizes Rare Disease Day and Supports Global Effort to “Reframe Rare” By Highlighting the Challenges of Cholestatic Liver Disorders
finance.yahoo.com - February 27 at 12:35 PM
Did Changing Sentiment Drive Albireo Pharma's (NASDAQ:ALBO) Share Price Down By 17%?Did Changing Sentiment Drive Albireo Pharma's (NASDAQ:ALBO) Share Price Down By 17%?
finance.yahoo.com - February 27 at 12:35 PM
Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March 2Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March 2
finance.yahoo.com - February 24 at 1:02 PM
Albireo Pharma: View Ahead Of Phase 3 Data In Progressive Familial Intrahepatic Cholestasis In Mid-2020Albireo Pharma: View Ahead Of Phase 3 Data In Progressive Familial Intrahepatic Cholestasis In Mid-2020
seekingalpha.com - February 11 at 7:29 AM
Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters Option to Purchase Additional SharesAlbireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters' Option to Purchase Additional Shares
www.marketwatch.com - February 3 at 7:04 PM
Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional SharesAlbireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - February 3 at 7:04 PM
Albireo down 11% premarket after pricing equity offeringAlbireo down 11% premarket after pricing equity offering
seekingalpha.com - January 30 at 7:33 AM
Albireo Prices $40 Million Public Offering of Common StockAlbireo Prices $40 Million Public Offering of Common Stock
finance.yahoo.com - January 30 at 12:34 AM
Albireo lower after proposing stock offeringAlbireo lower after proposing stock offering
seekingalpha.com - January 29 at 7:34 PM
Albireo Achieves Significant Milestones for Odevixibat Across Multiple DiseasesAlbireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases
finance.yahoo.com - January 29 at 7:34 PM
Albireo Announces Proposed Public Offering of Common StockAlbireo Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 29 at 7:34 PM
Albireo Joins with Alagille Syndrome Community in Celebrating First International Awareness DayAlbireo Joins with Alagille Syndrome Community in Celebrating First International Awareness Day
finance.yahoo.com - January 23 at 8:29 AM
Do Hedge Funds Love Albireo Pharma, Inc. (ALBO)?Do Hedge Funds Love Albireo Pharma, Inc. (ALBO)?
finance.yahoo.com - December 19 at 11:43 PM
Is Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Salary Justified?Is Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Salary Justified?
finance.yahoo.com - December 17 at 8:56 AM
Albireo to Present at the Jefferies 2019 London Healthcare ConferenceAlbireo to Present at the Jefferies 2019 London Healthcare Conference
finance.yahoo.com - November 14 at 4:26 PM
Albireo Pharma, Inc. (ALBO) Q3 2019 Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) Q3 2019 Earnings Call Transcript
www.nasdaq.com - November 6 at 10:57 PM
Were Hedge Funds Right About Souring On Albireo Pharma, Inc. (ALBO)?Were Hedge Funds Right About Souring On Albireo Pharma, Inc. (ALBO)?
finance.yahoo.com - November 6 at 5:56 PM
Albireo Reports Third Quarter 2019 Financial Results and Provides Business UpdateAlbireo Reports Third Quarter 2019 Financial Results and Provides Business Update
finance.yahoo.com - November 6 at 12:52 PM
Albireo Appoints Michelle Graham as Chief Human Resources OfficerAlbireo Appoints Michelle Graham as Chief Human Resources Officer
finance.yahoo.com - November 4 at 8:42 AM
Will Albireo Pharma (NASDAQ:ALBO) Spend Its Cash Wisely?Will Albireo Pharma (NASDAQ:ALBO) Spend Its Cash Wisely?
finance.yahoo.com - November 2 at 12:27 PM
Albireo to Report Third Quarter 2019 Financial...Albireo to Report Third Quarter 2019 Financial...
www.benzinga.com - October 30 at 11:03 AM
Albireo to Report Third Quarter 2019 Financial Results on November 6, 2019Albireo to Report Third Quarter 2019 Financial Results on November 6, 2019
finance.yahoo.com - October 30 at 11:03 AM
Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis FamiliesAlbireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families
finance.yahoo.com - October 3 at 9:27 AM
Is Albireo Pharma, Inc. (NASDAQ:ALBO) A Volatile Stock?Is Albireo Pharma, Inc. (NASDAQ:ALBO) A Volatile Stock?
finance.yahoo.com - September 19 at 9:15 PM
Albireo to Participate in Upcoming Investor ConferencesAlbireo to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 3 at 10:33 AM
This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.